Tuesday, October 19, 2021 Daily Archives

A Scalable Platform for GMP and High-Quality Plasmid Manufacturing

by

This webcast features: Dr. Mack Kuo, Associate Director BioProcess Development, Wacker Biotech US Inc. Demand for high-quality good manufacturing practice (GMP) plasmid DNA has grown significantly in the past few years. The recent proliferation of mRNA manufacturing, DNA vaccines, viral vector production, CAR T-cell therapies, and CRISPR gene editing technologies have all contributed to a bottleneck in availability of plasmid manufacturing capability. With decades of collective plasmid DNA manufacturing experience, the staff at Wacker Biotech US have released over 100…

October 19, 2021

PTC opens gene therapy NJ plant

by

PTC Therapeutics has opened its gene therapy manufacturing facility in Hopewell, New Jersey set to support production and research operations. PTC leased the facility in July 2020 and has since invested around $20 million at the site to develop a biologics plant that supports gene therapy research and production. Now, the 220,500 square-foot facility is open and consists of office, manufacturing, and laboratory space. According to the firm, the Hopewell facility can handle process development and manufacturing services for PTC’s…

October 19, 2021

Room for both allogeneic and autologous in cell therapy space

by

Allogeneic products may dominate the cell therapy sector thanks to tech and cost advantages but there will always be room for autologous treatments say experts. Cell therapies are either allogenic – derived from a universal donor – or patient-specific, autologous products. The products treat disease in the same way, what differs is the types of immune responses they generate and the process used to make them. And – according to a panel of experts at the BPI East conference in…

October 19, 2021